共 50 条
- [1] Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study[J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S866 - S867Janssen, HarryLampertico, PietroChen, Chi-YiHeo, JeongFournier, ClaireAhn, Sang HoonTsang, Tak Yin OwenCoffin, CarlaReggiani, Giulio MarchesiniHuang, Yi-HsiangHui, Aric JosunElkhashab, MagdyChen, Chien-HungJafri, Syed Mohammed RazaTan, SusannaMo, ShuyuanSuri, VithikaFlaherty, John F.Gaggar, AnujSubramanian, ManiAgarwal, KoshChuang, Wan-LongGane, EdwardLim, Young-Suk
- [2] EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY[J]. HEPATOLOGY, 2019, 70 : 306A - 307AJanssen, Harry L. A.Lim, Young-SukGane, Edward J.Fournier, ClaireAhn, Sang HoonTsang, OwenChuang, Wan LongHeo, JeongHui, Aric JosunElkhashab, MagdyChen, Chi-YiSu, Wei-WenFlaherty, John F.Gaggar, AnujTan, SusannaLau, Audrey H.Suri, VithikaMo, ShuyuanSubramanian, ManiJafri, Syed-MohammedAgarwal, KoshLampertico, PietroMarchesini, GiuloCoffin, Carla S.Huang, Yi-Hsiang
- [3] Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Hepatic Impairment: Week 48 Results From a Phase 2 Open Label Study[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S567 - S567Bae, Ho S.Lim, Young-SukTrinh, HuyHeo, JeongChuang, Wan-LongHui, Aric JosunElkhashab, MagdyTan, Susanna K.Mo, ShuyuanGuion, MatthewJump, BelindaFlaherty, JohnSuri, VithikaGaggar, AnujTsang, Tak Yin OwenAndreone, PietroJanssen, Harry
- [4] Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study[J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S872 - S872Lim, Young-SukLin, Chun-YenHeo, JeongBae, HoChuang, Wan-LongHui, Aric JosunElkhashab, MagdyTrinh, HuyTan, SusannaMo, ShuyuanFlaherty, John F.Suri, VithikaGaggar, AnujSubramanian, ManiTsang, Tak Yin OwenRyder, StephenAndreone, PietroJanssen, Harry
- [5] SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY[J]. HEPATOLOGY, 2019, 70 : 316A - 317ALim, Young-SukLampertico, PietroBae, Ho S.Chuang, Wan LongHeo, JeongHuang, Yi-HsiangHui, Aric JosunLin, Chun-YenFournier, ClaireFlaherty, John F.Gaggar, AnujLau, Audrey H.Mo, ShuyuanSuri, VithikaSubramanian, ManiTrinh, Huy N.Tsang, OwenRyder, Stephen D.Janssen, Harry L. A.Chen, Chien Hung
- [6] SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY[J]. GASTROENTEROLOGY, 2020, 158 (06) : S1320 - S1321Coffin, CarlaLim, Young-SukBae, HoHeo, JeongHui, Aric J.Chen, Chien-HungFlaherty, John F.Gaggar, AnujMo, ShuyuanHahambis, Thomas A.Jump, BelindaTrinh, Huy N.Tsang, OwenJanssen, Harry L.
- [7] EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY[J]. GASTROENTEROLOGY, 2020, 158 (06) : S1319 - S1320Bae, HoTrinh, Huy N.Janssen, Harry L.Fournier, ClaireChuang, Wan-LongHeo, JeongChen, Chi-YiFlaherty, John F.Gaggar, AnujTan, SusannaMo, ShuyuanNaik, SarjitaYee, LelandJafri, Syed-MohammedLampertico, PietroCoffin, CarlaLim, Young-Suk
- [8] Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (08): : 718 - 733Janssen, Harry L. A.Lim, Young-SukLampertico, PietroHeo, JeongChen, Chi-YiFournier, ClaireTsang, Tak Yin OwenBae, HoChen, Chien-HungCoffin, Carla S.Ahn, Sang HoonTrinh, HuyFlaherty, John F.Abramov, FridaZhao, YangLiu, YangLau, AudreyGerman, PolinaChuang, Wan-LongAgarwal, KoshGane, Edward
- [9] Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study[J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S755 - S756Lim, Young-SukLin, Chun-yenHeo, JeongBae, HoChuang, Wan-LongTsang, Tak Yin OwenFournier, ClaireHui, Aric JosunHuy TrinhTan, SusannaZhao, YangFlaherty, John F.Suri, VithikaGaggar, AnujBrainard, DianaRyder, StephenJanssen, Harry L. A.
- [10] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS[J]. GUT, 2019, 68 : A142 - A143Chan, Henry Lik YuenLampertico, PietroButi, MariaFung, ScottAhn, Sang HoonChuang, Wan-LongTak, Won YoungRamji, AlnoorChen, Chi-YiTam, EdwardBae, HoMa, XiaoliFlaherty, JohnGaggar, AnujLau, AudreyFeierbach, BecketWu, GeorgeSuri, VithikaSubramanian, ManiHuy TrinhYoon, Seung-KewAgarwal, KoshLim, Young-Suk